Ovarian Clear Cell Carcinoma

Similar documents
Current Concept in Ovarian Carcinoma: Pathology Perspectives

Background. Background. Background. Background 2/2/2015. Endometriosis-Associated Ovarian Cancer: Malignant Transformation of Endometriosis

Ovarian carcinoma classification. Robert A. Soslow, MD

ENODMETRIAL CARCINOMA: SPECIAL & NOT SO SPECIAL VARIANTS

How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens

3 cell types in the normal ovary

of 20 to 80 and subsequently declines [2].

Mody. AIS vs. Invasive Adenocarcinoma of the Cervix

3 cell types in the normal ovary

International Society of Gynecological Pathologists Symposium 2007

Dr Sanjiv Manek Oxford. Oxford Pathology Course 2010 for FRCPath Illustration-Cellular Pathology. Oxford Radcliffe NHS Trust

Endometrial Metaplasia, Hyperplasia & Other Cancer Mimics: a Consultant s Experience

Pathology of Ovarian Tumours. Dr. Jyothi Ranganathan MD ( Path) AFMC Pune PDCC (Cytopathology) PGI Chandigarh

Note: The cause of testicular neoplasms remains unknown

ACCME/Disclosures. Risk of Gyne Ca in HBOC. Molecular basis of HBOC. Hereditary Ovarian and Breast Cancer Syndrome

3/24/2017. Disclosure of Relevant Financial Relationships. Mixed Epithelial Endometrial Carcinoma. ISGyP Endometrial Cancer Project

Various hereditary, acquired and neoplastic conditions can lead to cyst formation in the kidney.

Disclosure. Relevant Financial Relationship(s) None. Off Label Usage None MFMER slide-1

Section 1. Biology of gynaecological cancers: our current understanding

Adenocarcinoma of the Cervix

Mousa. Najat kayed &Renad Al-Awamleh. Nizar Alkhlaifat

Mucinous Tumors of the Ovary Beirut, Lebanon. Anaís Malpica, M.D. Professor Department of Pathology

Interesting Cases in Gynecologic Pathology. Michael Ward, MD Surgical Pathology Fellow University of Utah Health Sciences Center Salt Lake City, UT

Female Genital Tract Lab. Dr. Nisreen Abu Shahin Assistant Professor of Pathology University of Jordan

Diagnostically Challenging Cases in Gynecologic Pathology

Case Report Ovarian Seromucinous Borderline Tumor and Clear Cell Carcinoma: An Unusual Combination

6/5/2010. Outline of Talk. Endometrial Alterations That Mimic Cancer & Vice Versa: Metaplastic / reactive changes. Problems in Biopsies/Curettages

Case presentation 04/13/2017. Genomic/morphological classification of endometrial carcinoma

Objectives. Atypical Glandular Cells. Atypical Endocervical Cells. Reactive Endocervical Cells

Ovarian cancer: 2012 Update Srini Prasad MD Univ Texas MD Anderson Cancer Center

Male Genital Cancers in the US in Frequency of Types

Synonyms. Nephrogenic metaplasia Mesonephric adenoma

Case 3 - GYN. History: 66 year old, routine Pap test. Dr. Stelow

Pacific Northwest Society of Pathologists Fall Meeting September 2015 Intraoperative Consultation in Gynecological Pathology: The Adnexal Mass

Spectrum of Preneoplastic and Neoplastic Cystic Lesions of the Kidney in Adult. by dr. Banan Burhan Mohammed Lecturer in Pathology Department

Low-grade serous neoplasia. Robert A. Soslow, MD

Salivary Glands 3/7/2017

The Diagnostic Challenges of Low Grade and High Grade Tubo-Ovarian Serous Carcinomas. W Glenn McCluggage Belfast, Northern Ireland

ACCME/Disclosures. M31078/07 Ondřej Hes 4/13/2016

Case Report. A Very Rare Occurrence of Synchronous Tumors of Variable Histology in Bilateral Ovaries

Triage of Ovarian Masses. Andreas Obermair Brisbane

Genetic Studies of Dysgerminoma

Updates in Urologic Pathology WHO Made Those Changes?! Peyman Tavassoli Pathology Department BC Cancer Agency

The role of immunohistochemistry in surgical pathology of the uterine corpus and cervix

5/26/2016. Pelvic Serous Carcinoma: 2014 W.H.O. Update. Outline of Talk. Changes to 2014 WHO system for pelvic serous tumors

OVARIES. MLS Basic histological diagnosis MLS HIST 422 Semester 8- batch 7 L13 Dr: Ali Eltayb.

Atypical Hyperplasia/EIN

Clinical History USCAP Specialty Conference. Gynecologic Pathology Case 3

A Serous Borderline Tumor of the Fallopian Tube Detected Incidentally

FREQUENCY OF NAPSIN A POSITIVITY IN OVARIAN CLEAR CELL CARCINOMA AND SEROUS CARCINOMA

Normal endometrium: A, proliferative. B, secretory.

Article begins on next page

Select problems in cystic pancreatic lesions

Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms

Case 1. Pathology of gynecological cancer. What do we need to know (Case 1) Luca Mazzucchelli Istituto cantonale di patologia Locarno

Papillary Cystadenoma of the Fallopian Tube Not Associated with von Hippel-Lindau Disease: A Case Report

Columnar Cell Lesions. Columnar Cell Lesions and Flat Epithelial Atypia

Presenter: Yeh-Han Wang M.D.

The relative frequency and histopathological patterns of ovarian lesions: study of 116 cases

Endosalpingiosis. Case report

Testicular Germ Cell Tumors; A Simplistic Approach

Characterizing Adnexal Masses: Pearls and Pitfalls 20 th Annual Summer Practicum SCBT-MR Jackson Hole August 11, 2010

64 YO lady THBSO for prolapse At gross : A 3 cm endometrial polyp in the fundus

Bases biológicas del cáncer de ovario en el siglo XXI

CYSTIC TUMORS OF THE KIDNEY JOHN N. EBLE, M.D. CYSTIC NEPHROMA

Endometrial Stromal Tumors

Patologia Molecular del Carcinoma de Ovario

3/27/2017. Pulmonary Pathology Specialty Conference. Disclosure of Relevant Financial Relationships. Clinical History:

JMSCR Vol 05 Issue 11 Page November 2017

Histopathological diagnosis of CUP

Pathology of the female genital tract

ACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI

What s (new) and Important in Reporting of Uterine Cancers Katherine Vroobel The Royal Marsden

Molecular Subtyping of Endometrial Cancer: A ProMisE ing Change

BLADDER CANCER EPIDEMIOLOGY

New Immunohistochemical Markers in the Evaluation of Primary Non-Glial Central Nervous System Tumors

Outline 11/2/2017. Pancreatic EUS-FNA general aspects. Cytomorphologic features of solid neoplasms/lesions of the pancreas

Tumors of kidney and urinary bladder

Pathobiology of ovarian carcinomas

Recent advances in breast cancers

New Developments in Immunohistochemistry for Gynecologic Pathology

Institute of Pathology First Faculty of Medicine Charles University. Ovary

What s New in Pathology of Genitourinary Tumors. Jiaoti Huang, MD, PhD Department of Pathology Duke University School of Medicine

Human epididymal protein 4 The role of HE4 in the management of patients presenting with pelvic mass Publication abstracts

Borderline Ovarian Tumours. Andreas Obermair Brisbane

Pancreatitis: A Potential Pitfall in Endoscopic Ultrasound Guided Pancreatic FNA

Papillary Lesions of the breast

Columnar Cell Lesions

Neoplasias Quisticas del Páncreas

Mammary analogue secretory carcinoma of salivary gland A case report of new entity

The incidence of cervical adenocarcinoma (ADC) has

Interpretation of p53 Immunostains. P53 Mutations are Ubiquitous in High Grade Serous Carcinoma. Diffuse strong positive nuclear staining

Urinary Bladder: WHO Classification and AJCC Staging Update 2017

Bibliography. Serous Tumors of the Ovary. Nomenclature

Endometrial pathology. Dr Tom Dodd and Dr Georgina England

Reporting of carcinoma of unknown primary tumour (CUP)

CA125 in the diagnosis of ovarian cancer: the art in medicine

L/O/G/O. Ovarian Tumor. Xiaoyu Niu Obstetrics and Gynecology Department Sichuan University West China Second Hospital

Neuroendocrine Lung Tumors Myers

OVARIAN CARCINOMA Immune Therapy. Antibodies to CA-125 (Ovarex) Vaccine therapy

Transcription:

Ovarian Clear Cell Carcinoma Rouba Ali-Fehmi, MD Professor of Pathology The Karmanos Cancer Institute, Wayne State University School of Medicine

50 year old woman with chief complaint of shortness of breath As part of her work up; PE abdominal pain and abdominal distention. Imaging study: cystic right adnexal mass with solid and cystic features. Patient underwent surgical resection.

Intraoperative Findings Right adnexal mass: 340 g, 9 x 8 x 6 cm, partially cystic, filled with bloody fluid.. The right fallopian tube was unremarkable.

Frozen Section Diagnosis:

Frozen Section Diagnosis: serous carcinoma

Final Diagnosis: Clear Cell Carcinoma

Clear Cell Carcinoma Most common cause for error at frozen section & permanent section in gynecologic pathology Often low mitotic index May not show marked nuclear atypia May not have clear cells Lots of other tumors have clear cells

Clear Cell Carcinoma Second most common surface epithelial carcinoma Associated with endometriosis ovarian and/or pelvic Almost always unilateral (>95%) Increased risk thromboembolism (x2.5) Poor response to cis-platinum therapy Presents in premenopausal age group as well as postmenopausal

Clear Cell Carcinoma Grossly

Ovary: Heterotopias Endometriosis

Clear Cell Carcinoma Papillary Tubulocystic (or glandular) Cystic Solid Often prominent hyalinized stroma or spherule-like mucoid stroma Fibromatous, fibroblastic, edematous stroma

Clear Cell Carcinoma Hobnail cells Clear or eosinophilic granular cytoplasm (glycogen) Signet ring cells containing mucin

CCC Associated with endometriosis ovarian and/or pelvic Cohort study in Denmark (1978-1998) Increased risk of OC in women with endometriosis restricted to 2 histologies Endometrioid (RR, 2.53; 95%CI 1.19-5.38) Clear cell (RR, 3.37; 95% CI 1.24-9.14) Brinton et al. Cancer Epidemiol Biomar Prev 2005;14:2929-35

CCC Associated with endometriosis ovarian and/or pelvic Endometriosis in up to 70% Atypical endometriosis may be seen adjacent to clear cell carcinoma

PTEN in Ovarian CCC PTEN inactivation may be early event in malignant transformation of endometriosis Mutations occur in both endometrial and ovarian carcinomas Histology Endometriotic Ovarian Cyst Endometrioid EOC Clear Cell EOC Inactivation (LOH) 13/23 (56.6%) 8/19 (42.1%) 6/22 (27.3%) Somatic PTEN Mutation 5/23 (20.6%) 4/19 (20%) 2/22 (8.3%) Sato et al. Cancer Res 2000;60:7052-6

At the molecular level

ARID1A AT-rich interactive domain 1A gene Tumor suppressor gene Encodes for BAF250a protein Plays critical role in SWI-SNF chromatin remodeling complex present in all eukaryotes Responsible for regulating critical cellular processes and gene expression

ARID1A in Ovarian CCC 50% of CCC and 30% of EC have mutations No proven clinical features/differences in outcomes associated with reduction/loss of expression of BAF250a by IHC

PIK3CA Mutations in Ovarian CCC Frequently co-mutated with ARID1A in CCC Observed in up to 40% of CCC Activation of PI3K AKT mtor-hif pathway Role of PI3K-mTOR inhibitors?

Ovarian Clear Cell Carcinoma IHC

IHC Negative ER, (90%) WT1, (85%) CK20, (95%) BAF250a, (20%) P53, (>85%) Positive HNF1β, (85%) Napsin A, (88%) CK7, (95%) PAX8, (85%) PAX2, (7%)

HNF1-β

PAX8

Diagnostic Reproducibly Diagnosis Kappa Translation Clear Cell Ca (CCC) 0.82 Excellent Serous Ca (SC) 0.59 Moderate Mixed Serous-Clear Ca (MSCC) 0.32 Fair Am J Surg Pathol 2008;32:955-64

ER- WT1- ER+ WT1+ Mixed CCC/S-CA rare, but they exist!

Grade in CCC Most exhibit range of nuclear atypia but some feature only low to moderate pleomorphism Mitotic index variable often low Architecture varies from well developed papillae to sheets of cells But, to date, no evidence that grading (nuclear, architecture, mitotic index) stratifies outcome

CCC: Cystic vs Adenofibromatous Adenofibromatous tumors may be better, but is this reflection of borderline, low stage cases? Cystic tumors may be better, but is this reflection of low tumor volume? Endometriosis tumors probably not better, but may be worse for mixed tumors (this may be reflection of stage)?

Ovarian Clear Cell Carcinoma: Diagnostic Problems Epithelial tumor: Borderline clear cell tumor Serous carcinoma Endometrioid carcinoma Mucinous carcinoma Mixed surface epithelial carcinoma Borderline serous tumor Germ line tumor: Yolk sac tumor Dysgerminoma Sex cord stromal tumor: Metastasis (esp. renal cell):

Borderline Clear Cell Tumor One or two cell layers Minimal to mild atypia Prominent fibromatous stroma Mitotic figures <1/10 hpf VERY RARE

Quiz time!

CCC HG Serous Ca

CCC Serous-CA Unilateral Hobnail cells Other patterns CCC WT1-, ER- HNF-1 beta+/- Bilateral Cytoplasmic clearing Other patterns S-CA WT1+, ER+ HNF-1 beta-/+

CCC vs. Ovarian Serous Carcinoma (SC) No convincing evidence that low stage CCC is more aggressive than low stage SC but low stage SC exceedingly rare High stage CCC does not respond to standard platinum-based therapy

Frozen Section Diagnosis:

Frozen Section Diagnosis: At least serous borderline tumor

Final Diagnosis: Clear Cell Carcinoma

Papillary CCC versus SBT Both may occur in younger patient population (reproductive age) May result in inadequate or delayed staging & therapy Requires extensive sectioning to determine correct diagnosis

CCC SBT Unilateral Monomorphic cell population Hobnail cells Endometriosis common Other patterns CCC WT1-/ER- Bilateral Mixed ciliated and pink cells Pink cell tufts Endometriosis uncommon Other patterns S-LMP WT1+/ER+

??

CCC SBLT

Serous Borderline

CAUTION: CCC can also be misdiagnosed as serous borderline tumor SBLT CCC

Napsin, neg

endometrioid CCC

CCC Endometrioid-CA Unilateral Hobnail cells Other patterns CCC WT1-, ER- HNF-1 beta+/- Unilateral, but may be bilateral Cytoplasmic clearing Other patterns E-CA WT1-, ER+ HNF-1 beta-/+

Endometrioid Carcinomas with Clear Cytoplasm Secretory carcinoma - subnuclear and supranuclear vacuoles, most of the time has low grade (nuclear grade 1-2) cytology Endometrioid carcinoma with clear cytoplasm, due to glycogen, lipid, other Squamous glycogenization has other areas of classic squamous differentiation

??

CCC Yolk Sac Tumor

Intraoperative Consultation Issues In the reproductive years, misdiagnosing yolk sac for CCC is especially problematic. Yolk sac: Limited, reproductive conservation surgery is standard of care. Chemotherapy is highly effective. CCC: Full cancer staging operation

OVARY EST

OVARY Clear cell

Yolk Sac Tumor

CCC AFP, negative Yolk Sac Tumor AFP, positive CK-7, positive CK-7, negative Glypican-3, negative Glypican-3, positive HNF1-beta, positive HNF1-beta, positive SALL4, negative SALL4, positive

AFP Glypican-3

SALL-4

Dysgerminoma

Solid CCC Dysgerminoma Polyhedral nuclei w/ inconspicuous nucleoli Lymphocytes and plasma cells PLAP-negative OCT3/4-negative CK7-positive Central, rounded nuclei w/ 1-4 nucleoli Lymphocytes and granulomas PLAP-positive OCT3/4-positive CK7-negative

PLAP OCT 3/4

CCC Steroid cell tumor Unilateral Yellow Other CCC patterns Cytokeratin pos Inhibin neg Calretinin neg Unilateral Yellow Uniform pattern Cytokeratin? Inhibin pos Calretinin pos

Clear Cell Renal Cell Carcinoma

When To Actively Exclude RCC Prior history of renal cell carcinoma Suspicion of a retroperitoneal mass Family history or renal cell carcinoma or evidence of hereditary renal cell carcinoma syndrome von Hippel-Lindau Hereditary leiomyomatosis Rare, but need to keep in consideration

CCC Renal Cell CA PAX8+ PAX2+ (<10%) HNF1β+ Unilateral Endometriosis PAX8+ PAX2+ (77%) HNF1β+ May be bilateral Renal mass or history of RCC

In conclusion, H&E

Thanks

Endometriosis-Associated Ovarian Cancer: A Distinct Clinical Entity? Younger Diagnosed at earlier stage Lower grade lesions Better prognosis (even when adjusting for stage)